Dr. Chapin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2006 - 2010- Massachusetts General HospitalResidency, Surgery, 2004 - 2006
Georgetown University School of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2010 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Urology Urology
- Join now to see all
Clinical Trials
- Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) Start of enrollment: 2013 Mar 18
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial Start of enrollment: 2024 Mar 29
Roles: Contact
Publications & Presentations
PubMed
- 100 citationsNCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas
Journal of the National Comprehensive Cancer Network. 2022-12-01 - 7 citationsA decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residentsMuammer Altok, Mary Achim, Surena F. Matin, Curtis A. Pettaway, Brian F. Chapin
Urologic Oncology. 2018-01-01 - 10 citationsOncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.Lamont Wilkins, Jeffrey J. Tosoian, Chad A. Reichard, Debasish Sundi, Weranja Ranasinghe
Cancer. 2021-05-01
Lectures
- Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial system...2019 ASCO Annual Meeting - 6/1/2019
- 7th Urologic Oncology: Advances in Clinical PracticeThe University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 11/2/2012
Press Mentions
2021 Urology Care Foundation Research Scholar Awardees AnnouncedApril 13th, 2021- Two-Time Cancer Survivor: MD Anderson Is Helping Me Beat the OddsDecember 1st, 2020
Preoperative mpMRI Possibly Beneficial in High-Risk Prostate CancerSeptember 16th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
